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Abstract 
Background: Adipose derived stromal cells (ASCs) are a rich and convenient source of cells for clinical regenerative 
therapeutic approaches. However, applications of ASCs often require cell expansion to reach the needed dose. In this 
study, cultivation of ASCs from stromal vascular fraction (SVF) over two passages in the automated and functionally 
closed Quantum Cell Expansion System (Quantum system) is compared with traditional manual cultivation.
Methods: Stromal vascular fraction was isolated from abdominal fat, suspended in α‑MEM supplemented with 10% 
Fetal Bovine Serum and seeded into either T75 flasks or a Quantum system that had been coated with cryoprecipi‑
tate. The cultivation of ASCs from SVF was performed in 3 ways: flask to flask; flask to Quantum system; and Quantum 
system to Quantum system. In all cases, quality controls were conducted for sterility, mycoplasmas, and endotoxins, in 
addition to the assessment of cell counts, viability, immunophenotype, and differentiation potential.
Results: The viability of ASCs passage 0 (P0) and P1 was above 96%, regardless of cultivation in flasks or Quantum 
system. Expression of surface markers and differentiation potential was consistent with ISCT/IFATS standards for the 
ASC phenotype. Sterility, mycoplasma, and endotoxin tests were consistently negative. An average of 8.0 × 107 SVF 
cells loaded into a Quantum system yielded 8.96 × 107 ASCs P0, while 4.5 × 106 SVF cells seeded per T75 flask yielded 
an average of 2.37 × 106 ASCs—less than the number of SVF cells seeded. ASCs P1 expanded in the Quantum system 
demonstrated a population doubling (PD) around 2.2 regardless of whether P0 was previously cultured in flasks or 
Quantum, while ASCs P1 in flasks only reached a PD of 1.0. Conclusion: Manufacturing of ASCs in a Quantum system 
enhances ASC expansion rate and yield significantly relative to manual processing in T‑flasks, while maintaining the 
purity and quality essential to safe and robust cell production. Notably, the use of the Quantum system entails signifi‑
cantly reduced working hours and thereby costs.
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Background
Experimental stromal cell therapy is rapidly emerging 
and provides opportunities for the treatment of diverse 
degenerative disorders and has progressed into the 
clinical trial arena for a variety of diseases [1]. Among 
mesenchymal stromal cells (MSCs) that have been thor-
oughly investigated, adipose derived stromal cells (ASCs) 
have shown to be one of the most promising stromal cell 
types with several advantages compared to other stromal 
cells. ASCs can be obtained with minimally invasive pro-
cedures such as liposuction. Moreover, the primary cell 




*Correspondence:  bjarke.follin.larsen@regionh.dk 
Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet University 
of Copenhagen, Juliane Maries Vej 20, Dept. 9302, 2100 Copenhagen, 
Denmark
Page 2 of 11Haack‑Sørensen et al. J Transl Med  (2016) 14:319 
example, MSCs from a bone marrow aspirate (BM-MSC). 
In  vitro expansion of ASCs leads to a multipotent cell 
population with the capacity to differentiate into several 
cell lineages. ASCs secrete many different growth fac-
tors and cytokines, have immunosuppressive properties, 
and there are essentially no ethical concerns for their use 
in diverse clinical applications [2–5]. Accordingly, ASCs 
have been extensively explored in the last few years.
Development of effective clinical cellular therapies using 
human autologous or allogeneic ASCs requires manufac-
turing of large numbers of cells. Production of a therapeu-
tically relevant cell product requires in vitro expansion to 
generate clinically relevant cell numbers. Cell processing 
must be performed in compliance with Good Manufac-
turing Practices (GMP) guidelines. This requires not only 
GMP-compliant reagents and materials but also standard-
ised processes with high reproducibility [6, 7].
Conventional flask-based cell culture is commonly used 
for large-scale production [8–10]. However, flask-based 
culture expansion is time and labour intensive with many 
open processing steps. Owing to the adherent nature of 
the ASCs, expansion requires a large surface area and 
multiple culture flasks resulting in significant inter-flask 
heterogeneity and increased risk of microbial contamina-
tion [6].
Automation of cell expansion within a GMP-compliant 
environment may mitigate or eliminate these problems. 
A potential solution is the use of bioreactors, which 
would ideally be closed systems that integrate various cell 
processing and cell culture steps within a single closed 
device. Such bioreactor systems should expand high 
cell numbers with minimal manipulation. Production 
in bioreactors should furthermore be superior to classi-
cal flask-based cell expansion, with regard to traceability, 
staff workload and costs [7].
The Quantum Cell Expansion System (Terumo BCT) 
is a commercial GMP compliant device. The system 
provides automated cell culture in a functionally closed 
environment, which includes a hollow fibre bioreactor. 
Pre-defined, customizable settings dictate how cells are 
seeded, continuously fed, and eventually harvested.
The Quantum system has been used by other research 
groups for culture expansion of BM-MSCs [11–14]. 
In this study, we investigated for the first time culture 
expansion of ASCs in the Quantum system as an alterna-
tive to conventional flask-based culture for efficient clini-
cal-scale ASC expansion.
The aim of this study was to evaluate the impact of 
automated and closed culture expansion in the Quantum 
system on ASC yield, viability, immunophenotype, purity, 
differentiation potential, and microbiological quality 




Lipoaspirates were obtained from 3 healthy female 
donors (age between 41 and 65  years) undergoing cos-
metic surgery (Printzlau Private Hospital). Each lipoaspi-
rate was processed to obtain stromal vascular fractions 
(SVF), from which ASC populations were expanded. The 
use of lipoaspirate has been approved by The National 
Committee on Health Research Ethics in Denmark, pro-
tocol no. H-3-2009-119. All donors signed an informed 
consent.
The experimental setup is illustrated in Fig. 1. Expan-
sion of ASCs was performed in a two-passage process 
using a traditional, flask-based process (F) or the Quan-
tum system (Q). Primary expansion of the SVF was per-
formed with both methods to produce ASC passage 0 
(P0) cells, which were further expanded in a second pas-
sage to produce ASC P1 cells. Using the two expansion 
methods over two passages, three production strategies 
were investigated: flasks to flasks (F–F), flasks to Quan-
tum system (F–Q), and Quantum system to Quantum 
system (Q–Q).
Preparation of lipoaspirate and SVF isolation
Liposuction of subcutaneous abdominal fat was per-
formed under local anaesthesia to provide approximately 
100  ml lipoaspirate from each donor. Each lipoaspirate 
was washed twice with phosphate-buffered saline (PBS) 
(Gibco, Life Technologies) to remove residual blood. The 
adipose tissue was digested by incubation with 0.6 PZ U/
ml collagenase NB4 (Serva GmbH) dissolved in Hank’s 
Balanced Salt Solution (10  ×  HBSS) (+CaCl2 +MgCl2, 
Fig. 1 Flowchart of the experimental setup. Comparability of ASC 
culture expansion, P0 and P1 in flasks (F) and Quantum Cell Expan‑
sion System (Q)
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Gibco, Life Technologies) diluted to a concentration of 
2 mM Ca2+ at 37 °C for 45 min under constant rotation. 
The collagenase was neutralised with complete medium 
containing Minimum Essential Medium, MEM Alpha 
(αMEM) without Ribonucleosides and Deoxyribonucle-
osides, (Gibco, Life Technologies), 1% Penicillin/Strep-
tomycin (10,000 U/ml and 10.000  µg/ml, respectively) 
(Gibco, Life Technologies) and 10% Fetal Bovine Serum 
(FBS) (Gamma irradiated, Australian origin, Gibco, 
Life Technologies) according to a well-established pro-
tocol [15, 16] after which the suspension was filtered 
through a 100 µm mesh (Cell Strainer, BD Falcon), cen-
trifuged at 1200g for 10 min at room temperature (RT), 
and re-suspended. The number of cells in the isolated 
SVF was counted using a NucleoCounter® NC-100™ 
(ChemoMetec).
Cell culture in flasks
Primary cell cultures of ASCs were established by seed-
ing 4.5 × 106 SVF cells per T75-flask (Nunc, Thermo Sci-
entific) in complete medium. The chosen seeding density 
of SVF in flasks has been optimized previously in our 
laboratory.
The cells were incubated at standard conditions at 
37 °C in humid air with 5% CO2. The culture medium was 
changed 3 days after the cells were seeded, thus remov-
ing non-adherent cells. Subsequently, the medium was 
changed every 3–4 days throughout the remainder of the 
culture period.
Reaching a confluence level of approximately 90%, the 
cells were harvested. For each T75 flask, the harvest pro-
cedure included an initial wash with 15 ml PBS, the addi-
tion of 3  ml TrypLE® Select (Gibco, Life Technologies), 
incubation for 10  min at 37  °C, and neutralisation with 
7  ml complete medium. The resulting suspension was 
centrifuged at 300g for 5  min at RT and re-suspended 
in complete medium. After counting, the cells were re-
seeded at 3.5 × 105 cells/T75-flask. Cell yields for ASCs 
at P0 and P1 were determined with a NucleoCounter® 
NC-100™ and calculated as means of three T75 flasks.
Cell culture in the Quantum system
The Quantum system is an automated and functionally 
closed system that integrates incubation, gas provision, 
and fluid handling for the management of a hollow fiber 
bioreactor. Operation of the Quantum system includes 
filling bags with media and reagents (e.g., media, PBS, 
cells, TrypLE Select), connecting these bags to the Quan-
tum system via a sterile connection device (TSCD-II, 
Terumo), and controlling the system via a touch screen 
interface.
The Quantum system process in the current study 
used media and reagents that were consistent with those 
referenced in the “Cell Culture in Flasks” section. One 
additional reagent was used for coating of the bioreactor, 
as described in “Coating of culture surface area’’ section. 
Standard conditions for ASCs culture were maintained, 
including an incubation temperature of 37 °C and a pre-
mixed gas supply (StrandMøllen) providing 5% CO2 and 
20% O2, balanced with N2.
The Quantum system was prepared according to the 
manufacturer’s protocol for inserting of the disposable 
Cell Expansion Set (including the hollow fiber bioreac-
tor), into the Quantum system and priming it with PBS.
Coating of culture surface area
Prior to loading of cells, the culture surface area of the 
hollow fiber bioreactor must be coated. For this purpose, 
30 ml of pooled cryoprecipitate (Blood Bank, Rigshospi-
talet) diluted to 100 ml with PBS is loaded into the Quan-
tum system. Coating times of 4 and 24 h were tested, in 
order to test if both conditions provided sufficient coat-
ing for cell attachment. Upon completion of the coating 
period, PBS and residual cryoprecipitate were washed 
out of the system and replaced with complete medium. 
ASCs P2 (30 × 106) were loaded into the bioreactors for 
evaluation of the effect of coating time upon adhesion 
and growth.
Pools of cryoprecipitate were manufactured from 
fresh-frozen plasma from blood donors (blood types low 
titer A+) selected and screened according to Danish law 
about blood supply. Frozen plasma bags (−30  °C) were 
air-thawed slowly at 4  °C overnight. Plasma bags were 
centrifuged and cryoprecipitate separated from plasma in 
a CompoMat G5 blood component separator device (Fre-
senius KABI). The remaining cryoprecipitate was pooled 
from four donors and aliquoted into 30 ml portions.
Culture expansion of primary SVF in the bioreactor (P0)
For primary expansion of the SVF, the Quantum system 
was seeded with in average 80  ×  106 (52–100  ×  106) 
SVF suspended in 100 ml complete medium. Cells were 
allowed to attach for 24 h at static conditions, after which 
perfusion automatically began at 0.1 ml/min. After 3 days 
of cultivation, a washout was performed to remove any 
non-adherent cells.
Culture expansion of pre‑cultured ASCs in the bioreactor (P1)
For expansion of pre-cultured ASCs (i.e., those resulting 
from the primary expansion), the Quantum system was 
seeded with 30 ×  106 ASCs suspended in 100  ml com-
plete medium. A 24  h attachment period was provided, 
as consistent with the SVF expansion.
After the attachment period, complete medium was 
fed continuously into the system at increasing rates 
from 0.1  ml/min and gradually doubled up to 0.8  ml/
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min, maintaining lactate levels between 6 and 10  mM 
throughout the expansion. Growth of the cells was esti-
mated based on glucose consumption and lactate pro-
duction, as mentioned by Lambrechts et al. [17]. Samples 
from the supernatant were drawn from the sample port 
and glucose/lactate levels were measured with a blood 
gas analyzer ABL 835 FLEX (Radiometer).
Harvest of ASCs from bioreactor
Harvests were performed when lactate generation rates 
surpassed 6-9  mM/day at feeding rate 0.8  ml/min. The 
harvest process included a washout of the system with 
PBS, the addition of 180 ml TrypLE® Select, and a 15 min 
incubation time, after which the cells were flushed into 
the harvest bag using complete medium. Cell yields at P0 
and P1 were determined by a NucleoCounter® NC-100™.
Storage of cells
To be able to work with a single Quantum system cells 
need to be stored for up till 5  h while preparing a new 
Cell Expansion Set for successive expansion. To assess 
the impact of storage media on cell viability, we tested 3 
different storage media, at 4  °C and RT for a 5 h period 
and measured viability with a NucleoCounter® NC-100™ 
every hour. 10 × 106 ASCs were re-suspended in 1 ml of: 
1. Isotonic saline (9 mg/ml) (Amgros I/S) with 1% human 
albumin (1% HA) (20%, CSL Behring GmbH) 2. Isotonic 
saline with 20% human albumin (20% HA) 3. Isotonic 
saline with 20% autologous human serum (20% HuS).
After 5 h incubation, 1 ×  106 ASCs from each condi-
tion were seeded into T75 flasks. Attachment and mor-
phology of ASCs was verified by microscopy after 24 h.
Immunophenotyping by flow cytometry
Adipose derived stromal cells P0 and P1 culture 
expanded in a Quantum system or flasks were analyzed 
by flow cytometry (Navios, Beckman Coulter). Cells 
from T75 flasks were detached by incubation with Try-
pLE® for 5–10 min at 37° C, and washed with FACS-PBS 
mixture [FACS-PBS (Hospital pharmacy, Copenhagen, 
Denmark), 1% EDTA (Hospital pharmacy, Copenha-
gen)], and 10% new born calf serum (GIBCO, Life Tech-
nologies). Harvested cells from a Quantum system were 
washed with 3 mL FACS-PBS mixture. After centrifuga-
tion (5  min at 300g), all cell pellets were re-suspended 
in FACS-PBS mixture, filtered, and distributed to FACS 
tubes with or without antibodies. The cells were incu-
bated for 30 min. at room temperature with the following 
antibodies or isotypes: Cluster of Differentiation (CD)45-
phycoerythrincyanin (PC7), CD34-allophycocyanin 
(APC), CD90-fluorescein isothiocyanate (FITC), CD73-
phycoerythrin (PE), CD13-phycoerythrin and Texas red 
energy coupled dye (ECD), CD29-FITC, HLA-DR-FITC, 
CD19-ECD, CD14-PC7, IgG2a-FITC, IgG1-ECD, IgG1-
APC, MsIgG1-PC7 (all Beckman Coulter), CD105-PE 
(R&D Sciences), CD166-PE, CD106-FITC, CD31-FITC, 
CD36-FITC, IgG1-PE, IgG1-FITC (all BD Bioscience). 
After incubation, the cells were washed with FACS-PBS 
mixture, centrifuged, and re-suspended in PBS before 
measuring on a Navios flow cytometer (Beckman Coul-
ter) using a six-colour protocol. The mentioned isotype 
controls and Fluorescence Minus One tubes were run 
with each analysis. Viability was determined by addition 
of SYTOX blue 5 min. prior to analysis (SYTOX®, Invit-
rogen, Life Technologies). Dead cells were excluded from 
the final analysis, and data was analyzed using Navios 
software and Kaluza (Beckman Coulter).
Differentiation potential of ASC
Adipose derived stromal cells P2 harvested from a Quan-
tum system and flasks were tested for their ability to dif-
ferentiate into osteoblasts, adipocytes and chondrocytes 
lineages, as described in our previous publication using 
StemPro differentiation kit (Gibco, Life Technology), 
according to the manufacturer’s protocols [18].
Microbial contamination assays
Cell culture supernatants were collected from the Quan-
tum system and from the culture flasks immediately 
before harvest. Microbial controls for bacteria and fun-
gus were performed on supernatants using aerobic and 
anaerobic BacT/ALERT iFN and iFA plus culture bottles 
(Biomerieux) and the BacT/ALERT® Microbial Detec-
tion System (Biomerieux).
Presence of mycoplasmas in cell culture supernatants 
were detected by PCR for mycoplasma genus at Statens 
Serum Institute, Copenhagen, Denmark. The content 
of endotoxins in end cell products were quantitatively 
determined by the Limulus amebocyte lysate (LAL) chro-
mogenic method, by Statens Serum Institute.
Statistics
Population doublings (PDs) were calculated from P1 
using the following formula: PD =  (log N −  log N0)/log 
2, where N is the number of harvested cells and N0 is the 
number of seeded cells.
PD calculations were shown to produce normally dis-
tributed data, when using cell counts from culture in 
flasks or a Quantum system. Equality of variance was 
confirmed by Levene’s test. A one-way ANOVA with 
Bonferroni correction was used for comparison of PD in 
Quantum–Quantum, flask–flask, and flask-Quantum in 
P1. All statistics were performed using IBM SPSS version 
19. Graphs were made using SPSS and Excel 2010 (Micro-
soft Inc.). Data are depicted as mean  ±  Standard Error 
Mean in figures, and mean ± standard deviation in tables.
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Results
Comparison of cell yield in culture flasks and Quantum 
system
Yield of cells obtained during P0 and P1 were compared 
for three donors. Loading cells in suspension into the 
Quantum system it is estimated that 30% of loaded vol-
ume, and thereby 30% of cells, are lost in residual space 
in tubes. This loss is based on a direct calculation of lines 
volumes according to the manufacturer; therefore only 
70% of loaded cells enter the actual bioreactor for attach-
ment and cell culture. This estimated cell loss has been 
taken into account in all cell yield calculations in pre-
sented results.
The cell growth in Quantum was estimated by moni-
toring glucose and lactate metabolism in culture media.
Cell yield in P0
An average seeding density of 5.56 × 107 (±1.76 × 107) 
SVF cells (corresponding to 70% of loaded cells) loaded 
into a Quantum system yielded 8.96 × 107 (±4.88 × 107) 
ASCs P0, which equals 1.61 times the total number of 
SVF cells seeded, within a 24  day culture period (mean 
15 ± 8.54 days) (Table 1).
In T75 flasks 4.5  ×  106 SVF cells were seeded yield-
ing an average of 2.37  ×  106 (±8.83  ×  105) ASCs P0, 
which only equals 0.53 times the total number of SVF 
initially seeded, within a 10  day culture period (mean 
8 ±  1.41  days) (Table  1). As the exact number of ASCs 
contained in a heterogeneous SVF is unknown, calcula-
tion of PDs is not an option for initial passage. Of notice, 
to maintain a viable and proliferative culture in flasks, the 
seeding density of SVF cells per cm2 was 22 times higher 
in flasks compared to the Quantum system.
Population doublings in passage 1
The ASCs P1 in Quantum systems proliferated faster and 
had significantly higher PDs compared to flasks, regard-
less of flask or Quantum system origin (p  <  0.05). The 
number of PDs for ASCs P1 passaged from Quantum to 
Quantum (Q–Q) was 2.18, and number of PDs for ASCs 
P1 passaged from flasks to Quantum (F-Q) was 2.23. 
ASCs P1 passaged on from flask into new flasks (F–F), 
reached 1.10 PDs, with a comparable number of days 
in culture. As for P0 cultures, seeding density of ASCs 
P1 was higher (approximately 5 times) in flasks than in 
Quantum in order to maintain viable and proliferative 
cultures. Viability of ASCs P0 and P1, regardless of cul-
tivation in flasks or Quantum, was above 96% (Table 1).
Microbial tests
Microbial tests for aerobic and anaerobic bacteria and 
fungus and mycoplasmas from culture supernatants were 
all negative, and the endotoxin concentration in all final 
cell preparations was less than 10 IU/ml.
Comparison of ASC phenotype in culture flasks 
and Quantum system
Adipose derived stromal cell immunophenotype was 
documented according to the Joint statement of the 
International Federation for Adipose Therapeutics and 
Science (IFATS) and the International Society for Cellu-
lar Therapy (ISCT) [19]. Immunophenotype was identi-
fied for ASCs P0 and P1 culture expanded in flasks and 
Quantum systems.
Immunophenotype P0
The populations of ASCs P0 from flasks and Quantum 
systems were almost identical. More than 80% of the cells 
in P0 were positive for CD105, CD90, CD73, and CD13, 
and around 70% for CD166. Approximately 20–30% of 
the P0 population was positive for CD34, CD146, and 
CD36, with CD146 higher levels on ASCs from flasks. 
CD45 and CD14 were low expressed, while HLA-DR, 
CD19, CD31, and CD106 were negative (Fig. 2).
Immunophenotype P1
After the first passage, ASCs P1 had increased expres-
sion of CD105, CD90, CD73, CD13, and CD166 to >95%, 
and CD45 and HLA-DR were negatively expressed for all 
culture conditions and was consistent with ISCT/IFATS 
Table 1 Cell yields. Number of cells seeded and final number of cells obtained after ASC expansion P0 and P1 in flasks 
and Quantum System
Results are expressed as the mean number (±SD) obtained from three donors
n = 3 SVF seeded SVF seeded per cm2 Mean days in culture ASC P0 harvested Viability ASC:SVF ratio
Flask (T75) 4.50 × 106 6.00 × 104 8 ± 1.41 2.37 ± 0.88 × 106 97% 0.53 ± 0.01
Quantum 5.56 ± 1.76 × 107 2.65 × 103 15 ± 8.54 8.93 ± 4.88 × 107 96% 1.61 ± 0.01
n = 3 ASC P0 ASC seeded per cm2 Mean days in culture ASC P1 harvested Viability PD
F–F 3.50 × 105 4.67 × 103 17 ± 5.57 7.53 ± 0.77 × 105 98% 1.10 ± 0.15
Q–Q 2.10 × 107 1.00 × 103 18 ± 5.77 9.53 ± 0.58 × 107 96% 2.18 ± 0.09
F–Q 2.10 × 107 1.00 × 103 17 ± 6.03 9.91 ± 1.28 × 107 97% 2.23 ± 0.19
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criteria. CD34 and CD146 expressed to low levels (<20%). 
CD36 expression remained the same in Quantum, while 
it increased to approximately 40% in flasks (Fig. 2).
Trilineage differentiation potential of ASC
ASCs P2 that was either expanded in the Quantum sys-
tem or in flasks were tested for their ability to differen-
tiate toward osteogenic, adipogenic and chondrogenic 
lineages. The ASC were able to differentiate into each of 
the three lineages regardless of previous culture condi-
tions (Additional file 1: Fig. S1).
Impact of Quantum system coating time on ASC yield 
and phenotype
In order to facilitate adhesion of ASCs to the hollow fib-
ers inside the Quantum system, the fibers were coated 
with cryoprecipitate. To perform serial passages of fresh 
unpreserved cells with a single Quantum system only, the 
time spent on preparation for next passage needs to be 
short. As such the impact of a 4 and 24 h coating protocol 
was determined based on ASC yield and phenotype after 
P3 expansion. The duration of coating prior to loading 
of ASCs into Quantum systems did not affect cell yield. 
30 × 106 ASCs P2 from the same donor were loaded into 
two Quantum system (with 21 ×  106 cells reaching the 
hollow fibers, corresponding to 70%). After 3  weeks of 
expansion, 106  ×  106 ASCs (4  h) and 109  ×  106 ASCs 
(24  h) were harvested, respectively. Achieved PDs were 
2.3 and viability was 96%, regardless of duration of 
coating (Fig.  3a). In addition, there was no difference 
in ASC phenotype depending on time spent on coating 
(Fig. 3b).
Impact of pre‑load storage on ASC viability
Serial passaging in a Quantum system interrupted by 4 h 
coating protocols require optimization of ASC storage 
conditions to preserve ASC viability and function while 
next passage is prepared.
The results were consistent between tested donors and 
showed that two of the storage media tested; 20% human 
albumin (20% HA) and Isotonic saline with 20% autolo-
gous human serum (20% HuS) both proved to maintain 
more than 90% viable ASCs after 5 h storage at 4° C as 
well as at RT. Storage media holding isotonic saline with 
1% human albumin (1% HA) failed to maintain ASC via-
bility above 90% during 5 h storage (Fig. 4a).
Moreover, a visual inspection of the cell suspensions 
after 5 h storage showed that when re-suspended in 20% 
HA the ASCs did not clump or sediment but were kept in 
suspension thereby favouring uniform re-seeding of cells 
(Fig. 4b).
The function of the stored ASCs was verified by adhe-
sion tests, where 1 × 106 ASCs were seeded in T75 flasks 
after 5 h storage and attachment of ASCs was observed 
under a microscope after 24  h. Morphology of the cells 
is shown in Fig. 4c. Most of the seeded ASCs that were 
stored in 20% HA and 20% HuS attached to the surface 
of the flasks and had a spindle-shaped and fibroblast-like 
Fig. 2 Flow cytometry immunophenotyping of culture‑expanded ASCs P0 and P1 in flasks and Quantum System (n = 2). The expression is shown 
as percentage positive cells. Results are expressed as (mean ± SEM)
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morphology; however, more dead cells were visible in 
those flasks with 20% HuS. The adhesion capacity of re-
seeded ASCs stored in 1% HA was reduced and more 
floating dead cells was observed compared to the other 
two conditions at both 4 °C and RT.
Discussion
The success of clinical cell therapy depends on efficient, 
feasible, standardised, robust and reproducible manufac-
turing of the cell product. Currently, the gold standard 
for production of ASCs is flask-based. In this study, we 
present for the first time a comparison of ASCs culture 
expanded in conventional cell culture flasks and a closed 
Quantum system.
Adipose derived stromal cells were culture expanded 
over two passages in either cell culture flasks or a Quan-
tum system. Seeding density of SVF and ASCs for 
expansion in flasks, which has been optimized in our lab-
oratory, is 6.0 × 104 SVF and 4.7 × 103ASCs per cm2 in 
T75 flasks. In the Quantum system, according to advice 
from the manufacturer, a 22 times lower SVF cell density 
was used (2.7 × 103 per cm2) and almost 5 times less ASC 
P0 (1.0 × 103 per cm2). We do not use ASCs exceeding 
P1 for clinical experiments, which is why we did not test 
ASCs for more passages.
The fact that the total yield of ASCs from SVF is greater 
in Quantum systems than in flasks is not surprising, as 
the growth area is 280 times larger, and contact inhibition 
therefore is not an issue. The relevant measure for com-
parison of proliferation is therefore not cell yield, but PD.
During primary passage, expanding ASCs from ini-
tially seeded SVF, the exact number of ASCs seeded is 
not known. The SVF is a heterogeneous population of 
cells with an estimated content of ASCs around 2% [20]. 
However, calculating the ratio of ASCs obtained per 
SVF cell seeded, expansion in Quantum systems proves 
to be superior to flasks. With subsequent expansion of 
ASCs, the numbers of harvested ASCs P1 from Quan-
tum systems were similar regardless of initial expan-
sion in flasks or Quantum systems. The PDs achieved in 
Quantum systems were twice as high as in flasks. Studies 
have compared culture expansion of BM-MSC in flasks 
vs Quantum systems, and have reported twice as high 
a BM-MSC yield after two passages compared to flask 
cultivation [13, 14]. However, two other studies showed 
no significant differences in PDs when comparing cul-
ture expansion of BM-MSC in flasks and Quantum sys-
tems [12, 21]. Though the ASCs perform more extensive 
proliferation, they would not be suspected to be senes-
cent. ASCs in T75 flasks with FBS medium have been 
expanded for more than 10 cumulative PDs after P1, 
without displaying signs of senescence [22].
The Quantum system clearly favours cell proliferation 
and yield from very small initial SVF seeding densities. 
Fig. 3 Impact of the coating time. Two bioreactors were coated with cryoprecipitate in 4 and 24 h, respectively. a After 3 weeks cultivation, the 
same amount of cells was harvested from both Quantums with similar viability and PD. b ASC phenotype assessed by flow cytometry on ASCs 
seeded in Quantum coated for 24 h compared to ASCs seeded in Quantum coated for 4 h. The expression is shown as percentage positive cells
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This is likely explained by the dynamic culture conditions 
which provide continuous feeding and disposal of waste 
thereby reducing abrupt fluctuations in pH and local par-
acrine environments mediated by manual batch change 
of medium.
Another potential explanation for the lower PD in 
flasks is contact inhibition. With a limited amount of 
space, as in the flasks, the cells will stop proliferate rather 
early, resulting in a lower PD over the set time. This 
would occur in some sections of the flasks, even though 
the cells were passaged at a 90% overall confluence level 
[23]. To achieve similar culture conditions for ASCs in 
Quantum systems and flasks, the seeding density in the 
flasks was changed in one experiment to match the den-
sity in the Quantum system. However, the cells did not 
proliferate, and the ASC population never became homo-
geneous (data not shown).
A third potentially decisive factor is the use of cryopre-
cipitate in Quantum systems. Cryoprecipitate facilitates 
adhesion of ASCs in the bioreactor which does not have 
a cell culture treated hydrophilic surface like traditional 
T flasks. This could be the reason for the expansion of 
ASCs seeded in lower densities, though this is only spec-
ulations since cryoprecipitate coating has not been iso-
lated as a factor and compared with non-coating.
All in all, since superior cell yields can be obtained 
using lower seeding densities, the total cell yield per 
donor will ultimately be greater in a Quantum system. 
Results also demonstrated that it is possible to start the 
primary passage with SVF cells in culture flasks and 
Fig. 4 Storage of ASCs. a Cell viability was measured every hour, while ASCs were stored for 5 h in 3 different suspensions: 1% HA, 20% HA or 20% 
HuS at either RT or 4 °C. b Visual observation of cells stored in 3 mentioned storage media at RT. c ASCs from all storage conditions were seeded in 
culture flasks. Morphology and cell attachment ability of ASCs was evaluated after 24 h under a microscope. Representative phase contrast images 
at ×10 magnification. HA human albumin, HuS human serum, RT room temperature
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culture expand the subsequent passages in quantum and 
gain same cell yield as if SVF were cultured in Quantum 
system. This would be useful if the start material is too 
small to load a bioreactor.
Translation from manual cell culture to expansion 
of cells in Quantum systems demands biological coat-
ing in order to allow attachment of cells. Several studies 
that have used Quantum systems for culture expansion 
of BM-MSCs, have used fibronectin as a coating mate-
rial [11–14, 21]. However, clinical grade fibronectin can 
be very costly. In our study, we used pooled cryopre-
cipitate manufactured in the Blood Bank at our hospital 
(Rigshospitalet, University Hospital Copenhagen). Cryo-
precipitate is a concentrated blood product made from 
fresh frozen plasma and is in clinical use for patients with 
significant hypofibrinogenemia [24]. Cryoprecipitate 
contains diverse proteins involved in blood clotting,—
fibrinogen, factor VIII, factor XIII, von Willebrand Factor 
and also fibronectin [24]. Viral safety and potential risk of 
transmitting animal spongiform encephalopathy agents is 
handled by donor screening and serology, and traceabil-
ity of blood donors as secured through compliance with 
Danish law. Overall the risk of transmitting prions is neg-
ligible compared to commonly accepted use of FBS dur-
ing cell culture [6].
Our results demonstrated that coating the bioreac-
tor with cryoprecipitate for 4  h, which simplifies the 
setup considerably, is as effective as overnight coating 
with regard to cell yield and phenotype. Storage condi-
tions however have an effect on cell survival and likely 
also seeding efficiency. The optimal way to store the cells 
while coating a new bioreactor was in 20% HA at RT, 
where cells did not clump or sediment and maintained 
normal morphology and the ability to adhere. Further-
more storage in 20% HA seemed to wash out the impor-
tance of temperature.
Several studies have addressed the short time storage of 
BM-MSCs in different media for immediate administra-
tion in cell therapy, such as saline or dextrose [25] or 1% 
HA [26, 27]. The only study which used HA in concentra-
tions above 1%, found no difference between storage of 
MSCs in 1% HA and 5% HA, but observed a differences 
between HA from different vendors, which is potentially 
important in a clinical setup [27]. Over all, other studies 
have found good short-term viability of various MSCs 
regardless of used storage medium [28, 29]. However, we 
suggest that the ability to also maintain cells in single cell 
suspension is important for subsequent seeding and cul-
ture in the Quantum system.
Several critical quality attributes have been pro-
posed for cell-based products, which include identity 
of the product and its potency and safety [30]. Culture 
expanded ASCs, regardless of culture conditions showed 
to be a homogeneous population with a phenotype that is 
in consistence with ISCT/IFATS criteria [19].
Measurements of potency remain one of the biggest 
challenges for cell therapy product development [31]. 
One of the functional criteria for the identification of 
ASCs drawn by ISCT and IFATS is that ASCs are capable 
of trilineage differentiates toward osteogenic, adipogenic 
and chondrogenic lineages [19, 32]. Culture expanded 
ASCs from flasks and bioreactor all proved trilineage 
potential (data not shown). This may not be the most 
relevant potency assay for an ASC-based therapy, as it 
rarely addresses the expected clinical mode of action, 
but additional validated and standardized potency assays 
are simply not yet developed. At this point we argue that 
viability, adhesion and proliferative capacity are the best 
predictors of maintained cell function and thereby clini-
cal efficiency. These measures are contained in the pre-
sent study.
One of the major risks related to the production of 
ASCs as well as any other cell product intended for clini-
cal use is microbial contamination. Proper quality man-
agement and aseptic manufacturing is the focal point. 
Introducing the use of closed Quantum systems with 
automated feeding minimises the number of open man-
ual steps considerably with a shared impact on feasibil-
ity, reproducibility and safety. Notably, open processes 
require the highest possible clean area classification of 
facilities (Class 100/ISO 5/Grade A) whereas the use of 
closed systems may reach approval in lower classified 
areas. Used clean area classification has a major impact 
upon feasibility and costs for set up and maintenance.
Conclusion
Manufacturing of ASCs in a Quantum system enhances 
ASC expansion rate and yield significantly relative to 
manual processing in T-flasks, while maintaining the 
purity and quality essential to safe and robust cell pro-
duction. In addition, the use of cryoprecipitate for coat-
ing, the short 4 h coating time, and an optimized protocol 
for storage of the cell during this process validates the use 
of a single Quantum unit for expansion of a cell product 
for several passages. Notably, the use of the Quantum 
system also provides significant reduced staff and cost.
Additional file
Additional file 1: Fig S1. Differentiation of ASCs after culture in either 
T75 flasks or quantum system towards adipogenic, osteogenic, and 
chondrogenic lineage. Differentiation was evaluated by cytochemically 
staining with Oil Red O for adipogenic, Alizarin Red S for osteogenic, and 
Alcian Blue for chondrogenic.
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